Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Chen Hsuan Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4954-1011; OpenAlex author ID A5031750008. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 19

  1. Author Correction: Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Co-author DOI 10.1038/s41467-025-58613-9↗
  2. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Co-author DOI 10.1007/s13238-020-00760-4↗
  3. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  4. Preparation and In Vitro Evaluation of a Nano Ultrasound Contrast Agent Targeting Pancreatic Cancer. Co-author DOI 10.1166/jnn.2021.18883↗
  5. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  6. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  7. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Co-author DOI 10.1038/s41467-018-06136-x↗
  8. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Co-author DOI 10.7150/thno.23978↗
  9. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Co-author DOI 10.1038/ng.3568↗
  10. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  11. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗
  12. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. First author DOI 10.1038/nm.3686↗
  13. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2012-303477↗
  14. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. First author DOI 10.1093/carcin/bgt004↗
  15. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. Co-author DOI 10.1093/jnci/djt123↗
  16. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Co-author DOI 10.1158/1055-9965.epi-12-1458↗
  17. Prediagnostic body mass index and pancreatic cancer survival. Co-author DOI 10.1200/jco.2013.51.7532↗
  18. Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Co-author DOI 10.1093/carcin/bgr228↗
  19. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dongxin Lin · 11 shared papers, 2011–2025 · strength 0.81
  2. Xu Che · 7 shared papers, 2011–2021 · strength 0.41
  3. Jian Zheng · 5 shared papers, 2016–2021 · strength 0.37
  4. Xiaoping Miao · 5 shared papers, 2011–2025 · strength 0.32
  5. Xudong Huang · 4 shared papers, 2016–2021 · strength 0.31
  6. Jiang Chang · 4 shared papers, 2011–2025 · strength 0.30
  7. Chengfeng Wang · 5 shared papers, 2011–2021 · strength 0.29
  8. Yanfen Zheng · 3 shared papers, 2019–2021 · strength 0.26
  9. Ying Ye · 3 shared papers, 2019–2021 · strength 0.26
  10. Jiachun Su · 3 shared papers, 2019–2021 · strength 0.26
  11. Jialiang Zhang · 3 shared papers, 2019–2021 · strength 0.26
  12. Ling Pan · 3 shared papers, 2019–2021 · strength 0.26
  13. Rufu Chen · 3 shared papers, 2019–2021 · strength 0.26
  14. Ying Zhu · 2 shared papers, 2018–2025 · strength 0.24
  15. Jianbo Tian · 2 shared papers, 2018–2025 · strength 0.24
  16. Kun Huang · 2 shared papers, 2018–2025 · strength 0.24
  17. Rong Zhong · 2 shared papers, 2018–2025 · strength 0.24
  18. Ming Yang · 2 shared papers, 2018–2025 · strength 0.24
  19. Juntao Ke · 2 shared papers, 2018–2025 · strength 0.24
  20. Li Wang · 2 shared papers, 2018–2025 · strength 0.24
  21. Beibei Zhu · 2 shared papers, 2018–2025 · strength 0.24
  22. Edward L. Giovannucci · 6 shared papers, 2013–2016 · strength 0.20
  23. Zhi Rong Qian · 6 shared papers, 2013–2016 · strength 0.20
  24. Peter Kraft · 6 shared papers, 2013–2016 · strength 0.20
  25. Brian Matthew Wolpin · 6 shared papers, 2013–2016 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.